0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BBS21008

PD-1/CD80 bispecific antibody

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: PD-1/CD80 bispecific antibody
    Indications: Solid tumors such as lung cancer, gastric carcinoma, esophagus cancer, cervical cancer.
    Research phase: Pre-clinical, CMC developing;
    Cooperation demands: Project transfer or co-development. (the project’s company is in the startup stage and seek external cooperation to accelate drug research and development.)
  • Highlights
    1. The mechanism of this project is clear, there’re no such target bifunctional antibody in clinical stage globaly which has FIC potential;
    2. This project was developed to be 2.0 anti PD-1 drug , which can be used in combination with target HER2, AVASTIN, trop-2 in the future, with the potential of breaking anti PD-1 antibody’s current 20% low ORR;
    3. In vivo, this project’s inhibition of tumor growth activity was significantly higher than opdivo and keytruda, with a large amount of infiltrated CD8+ T cell ;
    4. This project was developed by the company’s own technique platform, which can enhance the combination of CD80 and PD-L1, CTLA-4, CD28. And this project’s protein is in natural structure form which has low possibility of ADA occurrence;
    5. Easily industrialization: expression level was more than 2g/L, with no mismatch, the protein’s one-step purification rate was more than 95%, making CMC more easily in the future.
  • Project Introduction

    1. Drug type: Double antibody fusion protein;

    2. Mechanism: three mechanisms in treating tumors: a) combining the immune checkpoint PD-1 and PD-L1 to break tumor suppressed immune system; b) combining CTLA-4 to inhibit Treg cell, silmilar to anti CTLA-4 drug Ipilimumab; c) combining CD28 to activate T cells;

    3. Indications: Solid tumors such as lung cancer, gastric carcinoma, esophagus cancer, cervical cancer;

    4. Research phase: Pre-clinical, CMC developing;

    5. Research progress: Completed double antibody construction and modification, affinity determination and in vitro functional validation. The highest expression level was 2.6g/L..


Comments (0)